Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02810457 · ClinicalTrials.gov registry record · Phase 3
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Centus Biotherapeutics Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 731
- Enrollment target
- 20
- Study locations
NCT02810457 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that has completed, run by Centus Biotherapeutics Limited. The registered enrollment target is 731 participants, above the 318-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (130% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT02810457, a Phase 3 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Centus Biotherapeutics Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 731 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG FKB238 (bevacizumab)
- DRUG Avastin (bevacizumab)
Study Locations (20)
Ohio
- Research Site 7805 - Hematology & Oncology Associates, Inc. - Canton
- Research Site 7801 - Gabrail Cancer Center - Canton
- Research Site 7804 - Tri-County Hematology & Oncology Associates, Inc. - Massillon
California
- Research Site 7814 - Compassionate Care Research Group - Fountain Valley
- Research Site 7811 - Innovative Clinical Research Institute - Whittier
Illinois
- Research Site 7812 - Joliet Oncology-Hematology Associates, Ltd. - Joliet
- Research Site 7810 - Edward H. Kaplan, MD and Associates - Skokie
Minsk Oblast
- Research Site 8501 - Lyasny
- Research Site 8504 - Minsk
Other
- Research Site 8606 - Banja Luka
- Research Site 8602 - Mostar
Florida
- Research Site 7803 - 21st Century Oncology - Jacksonville
North Dakota
- Research Site 7813 - Trinity Cancer Care Center - Minot
Texas
- Research Site 7809 - Millennium Oncology - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 731 participants |
| Start Date | 2016-09-07 |
| Est. Completion | 2022-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02810457
The ClinicalTrials.gov registry entry for NCT02810457 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 731 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 318-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (130% higher). The listed sponsor is Centus Biotherapeutics Limited, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT02810457 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ohio, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT02810457 about?
NCT02810457 is a clinical study titled "Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer". The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
What is the current status of trial NCT02810457?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 731 participants. The study started on 2016-09-07. Estimated completion is 2022-01-26.
What conditions does trial NCT02810457 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT02810457?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), FKB238 (bevacizumab) (DRUG), Avastin (bevacizumab) (DRUG).
Who is sponsoring clinical trial NCT02810457?
This trial is sponsored by Centus Biotherapeutics Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02810457 being conducted?
This trial has 20 study locations across California, Florida, Illinois, North Dakota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.